Boundless Bio, Inc. (BOLD) earnings
BOLD earnings moved a median of +0.34% by the close. Quarterly and annual BOLD reports and results, each read against the price at its own news timestamp. Back to the BOLD overview →
17 measured BOLD earnings events.
Where these BOLD earnings landedvs 17 measured BOLD earnings reactions
| Middle 50% of BOLD earnings reactions | 0.00% to +2.94% |
|---|---|
| Median reaction (to close) | +0.34% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 BOLD earnings events with a measured close landed between +0.00% and +2.94%; 53% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Boundless Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.30% | +3.21% | |
| Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights | Press release | +0.00% | -5.26% | |
| Form 10-Q Boundless Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -5.26% | |
| Form 10-K Boundless Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.68% | +1.79% | |
| Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | +1.59% | +0.00% | |
| Form 10-Q Boundless Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.59% | +0.00% | |
| Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | +0.00% | +0.00% | |
| Form 10-Q Boundless Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights | Press release | -7.49% | -13.77% | |
| Form 10-Q Boundless Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | -7.49% | -13.77% | |
| Form 10-K Boundless Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | — | +2.03% | |
| Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights | Press release | +1.18% | +2.94% | |
| Form 10-Q Boundless Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.18% | +2.94% | |
| Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results | Press release | +0.00% | +0.34% | |
| Form 10-Q Boundless Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.34% | |
| Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights | Press release | +1.88% | +11.87% | |
| Form 10-Q Boundless Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.88% | +11.87% |
Keep exploring
More BOLD: analyst actions → · SEC filings → · BOLD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIOSTAR PHARMS INC (BSPM) | 167 | 0.00% | 41% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 167 | -0.32% | 42% |
| CymaBay Therapeutics Inc. (CBAY) | 166 | +0.02% | 52% |
| Innoviva, Inc. (INVA) | 166 | +0.10% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.